# Royal Marsden NHS Foundation Trust

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/royal-marsden-nhs-foundation-trust/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 71.2 |
| Citations | 2,603,546 |
| City | London |
| Country | GB |
| Description | Royal Marsden NHS Foundation Trust is a research organisation in London, GB. OpenAlex records 17,874 works and 2,603,546 citations for it. 3,117 researchers list it as their most recent affiliation. |
| Homepage | http://www.royalmarsden.nhs.uk/pages/home.aspx |
| OpenAlex ID | https://openalex.org/I1325846038 |
| Researchers | 3,117 |
| ROR ID | https://ror.org/0008wzh48 |
| Type | healthcare |
| Wikidata ID | https://www.wikidata.org/wiki/Q7761706 |
| Works | 17,874 |

## University collaborators

- [Merck & Co., Inc., Rahway, NJ, USA (United States)](https://scholariq.org/institutions/merck-and-co-inc-rahway-nj-usa-united-states/)

## University papers

Showing 12 of 175.

- [Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-versus-chemotherapy-for-pd-l1-positive-non-small-cell-lung-cancer/)
- [Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer](https://scholariq.org/papers/docetaxel-plus-prednisone-or-mitoxantrone-plus-prednisone-for-advanced-prostate/)
- [Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck](https://scholariq.org/papers/nivolumab-for-recurrent-squamous-cell-carcinoma-of-the-head-and-neck/)
- [Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer](https://scholariq.org/papers/trastuzumab-after-adjuvant-chemotherapy-in-her2-positive-breast-cancer/)
- [Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy](https://scholariq.org/papers/increased-survival-with-enzalutamide-in-prostate-cancer-after-chemotherapy/)
- [Abiraterone and Increased Survival in Metastatic Prostate Cancer](https://scholariq.org/papers/abiraterone-and-increased-survival-in-metastatic-prostate-cancer/)
- [The repertoire of mutational signatures in human cancer](https://scholariq.org/papers/the-repertoire-of-mutational-signatures-in-human-cancer/)
- [Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline](https://scholariq.org/papers/management-of-immune-related-adverse-events-in-patients-treated-with-immune/)
- [Integrative Clinical Genomics of Advanced Prostate Cancer](https://scholariq.org/papers/integrative-clinical-genomics-of-advanced-prostate-cancer/)
- [Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers](https://scholariq.org/papers/inhibition-of-poly-adp-ribose-polymerase-in-tumors-from-i-brca-i-mutation/)
- [Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial](https://scholariq.org/papers/prednisone-plus-cabazitaxel-or-mitoxantrone-for-metastatic-castration-resistant/)
- [Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study](https://scholariq.org/papers/pembrolizumab-alone-or-with-chemotherapy-versus-cetuximab-with-chemotherapy-for/)

## University researchers

- [Johann S. de Bono](https://scholariq.org/researchers/johann-s-de-bono/)
- [Brandon Whitcher](https://scholariq.org/researchers/brandon-whitcher/)
- [Sarah Stapleton](https://scholariq.org/researchers/sarah-stapleton/)
- [Chloe Middleton‐Dalby](https://scholariq.org/researchers/chloe-middleton-dalby/)

## University top topics

Showing 8 of 25.

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Advanced Radiotherapy Techniques](https://scholariq.org/topics/advanced-radiotherapy-techniques/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Sarcoma Diagnosis and Treatment](https://scholariq.org/topics/sarcoma-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Medical Imaging Techniques and Applications](https://scholariq.org/topics/medical-imaging-techniques-and-applications/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.